Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

April 25, 2025

Invitation to Presentation of Egetis’ First Quarter 2025 Report on April 30, 2025

Read more

April 25, 2025

Article mapping variants in thyroid hormone transporter MCT8 to disease severity published in Nature Communications

Read more

Regulatory

April 11, 2025

Egetis Therapeutics’ Annual Report 2024 published

Read more

Upcoming event

April 30, 2025

Interim Report Q1 2025 (7:00am CEST)

Latest presentation

February 26, 2025

Year-end report 2024 (webcast)

Latest Report

February 26, 2025

Year-end report 2024

Calendar and upcoming reports

April 30, 2025

Interim Report Q1 2025 (7:00am CEST)

May 6, 2025

Annual General Meeting

August 21, 2025

Interim Report Q2 2025 (7:00am CEST)

November 7, 2025

Interim Report Q3 2025 (7:00am CET)

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]